Abstract:BACKGROUND:The objective of this report is to summarize common deficiencies identified in the filing reviews of abbreviated new drug applications (ANDAs) with clinical endpoint bioequivalence studies and skin irritation, sensitization, and adhesion (I/S/A) studies received by the US Food and Drug Administration (FDA) between 2007 and 2017, to help applicants avoid common deficiencies, minimize "refuse-to-receive" (RTR) actions, "information requests," and ANDA approval delays.METHODS:Multiple internal FDA databases were searched to evaluate and summarize common deficiencies identified in ANDA submissions containing clinical endpoint studies and skin I/S/A studies that required review by the Division of Clinical Review. A total of 275 ANDA submissions with filing reviews from January 2007 to June 2017 were analyzed in this report.RESULTS:Two hundred eighteen (79.3%) filing reviews contained one or more deficiencies. Seventy-nine (28.7%) ANDAs were issued RTR letters because of major clinical deficiencies, specifically bioequivalence and clinical deficiencies, accounting for 9% of overall identified deficiencies. Twenty-two other categories of deficiencies are summarized into 4 main categories: missing information related to the clinical studies other than data sets (38%), missing data sets (35%), formulation issues (12%), and organization/format issues (6%).CONCLUSIONS:The most common deficiency in the "missing information related to the clinical studies other than data sets" category was "missing clarification of information" (22%). We also noted that the Division of Filing Review has identified these same types of deficiencies since assuming responsibility of the filing assessment for ANDAs with clinical endpoint BE studies and skin I/S/A studies. In conclusion, to minimize "refuse-to-receive" actions, "information requests," and approval of ANDA delays for generic drug products, applicants should submit full clinical study reports, including all data sets for drug products recommending clinical studies.

Discussion on the problems in drug identification marker including labeling and packaging in the submission process of Abbreviated New Drug Application

Discussion on Labeling and Packaging in Application of ANDA

Investigation and Analysis of Domestic Pharmaceutical Firms to Obtain Approval of Preparation Abbreviated New Drug Application from FDA

Scientific Considerations for Stability Studies of Drug Substances Supporting Abbreviated New Drug Applications (ANDAs)

Regulations and Technical Guidelines of Drug Packaging Material's Compatibility Study in China, EU and USA

New Problems in FDA Problems in Drug Registration

Evaluation on New Drug Registration System in America and Its Illumination for China

Research and Analysis of 180 Package Inserts of Oral Chemical Prescription Drug

Discussion about Improvement of National Drug Standards

On the Amendments of China’s Provisions for Drug Registration

Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies.

Comparison of Marketing Authorization System for Drug Wholesale Enterprises between China and America

Drug Residue Issues of Aquatic Products Export from China

Access of Chinese Crude Drug to the USA Market

Scientific Medical Supervision in the Perspective of Off-label Uses

New Prospect on Research and Development of Chinese Materia Medica and Phytomedicines in Global

Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities

Analysis on the reasons for domestic pharmaceutical enterprises for relatively lower reporting proportion of adverse drug reaction

Abuse of Pharmaceuticals Over-packaging and the Redressing Policies

Study on Narcotics and Psychotropic Substances Control( Part Ⅴ):Comparative Study on Domestic and Foreign Control System of Narcotics and Psychotropic Substances

Registration and Regulatory Mode of API in China after Chemical Drug Registration Classification Reform